Thailanstatin A ADC Linkers for Controlled Cytotoxin Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) face challenges in achieving a suitable toxicity profile and efficient drug release mechanisms, particularly with cytotoxic agents like thailanstatin A analogs, which are potent inhibitors of eukaryotic RNA splicing, limiting their efficacy in cancer treatment.
Innovation Solution
Development of novel thailanstatin A analogs and toxin-linker compounds for ADCs, specifically designed with functional sites for attachment to antibodies, enabling controlled drug release and enhanced potency through targeted delivery to cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thalidomide is used to treat multiple myeloma, then anti-tumor activity is achieved, but teratogenicity and other adverse reactions occur
Solution Approach 1:
The patent modifies the chemical structure of thalidomide by replacing the terminal phenyl group with various substituted phenyl groups (e.g., fluorine, chlorine, methoxy substitutions at different positions). These parameter changes in molecular structure aim to maintain the glutarimide ring's anti-tumor activity while altering the side chain to reduce teratogenicity and other adverse effects.
Solution Approach 2:
The invention introduces specific local modifications at particular positions of the thalidomide molecule (e.g., substitution at positions 2, 3, or 4 of the phenyl group). These localized structural changes allow the molecule to retain its core anti-tumor function while modifying specific regions responsible for harmful effects.
2Reliability
If thalidomide is used to treat multiple myeloma, then anti-tumor activity is achieved, but peripheral neuropathy occurs
Solution Approach 1:
The patent employs parameter changes by introducing various substituents (fluorine, chlorine, alkyl groups, etc.) at different positions of the phenyl ring. These modifications alter the pharmacokinetic and pharmacodynamic properties of the molecule, aiming to preserve anti-myeloma activity while reducing neurotoxicity.
Solution Approach 2:
The invention creates composite molecular structures by combining the glutarimide core with modified phenyl groups containing various functional substituents. This composite approach allows optimization of therapeutic index by separating the anti-tumor activity (maintained in the core) from the toxic effects (modified in the substituent groups).
Data Source
Figure 1
AI summary
The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.